An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report

Hao,Lin; Sen,Sandeep; Sugumar,Dhivya

doi:10.3892/ol.2014.2754

February-2015 Volume 9 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2015 Volume 9 Issue 2

Full Size Image

Case Report

An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report

Authors:
- Lin Hao
- Sandeep Sen
- Dhivya Sugumar
View Affiliations / Copyright

Affiliations: Department of Internal Medicine, Saint Mary's Health Center, St. Louis, MO 63117, USA, SSM Cancer Care, Saint Mary's Health Center, St. Louis, MO 63117, USA
Pages: 749-751
|
Published online on: December 2, 2014

https://doi.org/10.3892/ol.2014.2754
Expand metrics +

Abstract

The current study presents the case of a 63‑year‑old patient exhibiting refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS‑T), who was positive for the MPL W515L mutation, but negative for the JAK2 V617F mutation. Following diagnosis, the patient remained asymptomatic for over three years, however, in August 2012, the patient relapsed and was administered with supportive treatment in the form of subcutaneous darbepoetin α at a dose of 300 µg/week, which resulted in an increased hemoglobin concentration, allowing the patient to remain transfusion‑independent. The MPL W515L mutation has been reported in two previous cases of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) with ringed sideroblasts, however, to the best of our knowledge, the current report is the first to present a case of RARS‑T with an MPL W515L mutation. A clinical trial designed to evaluate the efficacy of a targeted agent against the JAK2 V617F mutation is currently ongoing, with the aim of providing a novel therapeutic strategy for treating MDS/MPN patients. As MPL is located upstream of the JAK‑STAT signaling pathway, it is a possible therapeutic target in MDS/MPN patients positive for an MPL W515L mutation, but negative for a JAK2 V617F mutation.

View Figures

View References

1	Vardiman JW, Bennett JM, Bain BJ, et al: Myelodysplastic/myeloproliferative neoplasm, unclassifiable. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al: 4th edition. IARC Press; Lyon: pp. 85–86. 2008
2	Zikria J, Galili N, Tsai WY, et al: Thrombocytosis in myelodysplastic syndromes: not an innocent bystander. J Blood Disord Transfus. S3:0022012.
3	Schmitt-Graeff AH, Teo SS, Olschewski M, et al: JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 93:34–40. 2008. View Article : Google Scholar : PubMed/NCBI
4	Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
5	Taylor G, Culligan D and Vickers MA: Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia. Case Rep Hemato. 2013:7184802013.
6	Vigon I, Mornon JP, Cocault L, et al: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA. 89:5640–5644. 1992. View Article : Google Scholar : PubMed/NCBI
7	Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 108:3472–3476. 2006. View Article : Google Scholar : PubMed/NCBI
8	Beer PA, Campbell PJ, Scott LM, et al: MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 112:141–149. 2008. View Article : Google Scholar : PubMed/NCBI
9	Vannucchi AM, Antonioli E, Guglielmelli P, et al: Characteristics and clinical correlates of MP 515W>L/K mutation in essential thrombocythemia. Blood. 112:844–847. 2008. View Article : Google Scholar : PubMed/NCBI
10	Schnittger S, Bacher U, Haferlach C, et al: Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia. 22:453–455. 2008. View Article : Google Scholar
11	Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 24:1128–1138. 2010. View Article : Google Scholar : PubMed/NCBI
12	Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3:e2702006. View Article : Google Scholar : PubMed/NCBI